• Article highlight
  • Article tables
  • Article images

Article History

Received : 15-05-2021

Accepted : 07-06-2021

Available online : 27-07-2021

Article Metrics

Downlaod Files


Article Access statistics

Viewed: 170

PDF Downloaded: 121

Gohil, Noolvi, Patel, and Sen: Chemical classification of MDM2 inhibitors


MDM2 inhibitors (p53-MDM2 interaction inhibitors) are emerging class of the anti-cancer agents, which can selectively target the cancer cells over the normal cells.1 Many potential MDM2 inhibitors have been developed by the various developers, and they proved to be very efficient in non-genotoxic direct activation of p53 protein function in the cancer cells (apoptosis).

The reported MDM2 inhibitors are belongs to diverse chemicals classes. And they might be from natural origin or synthetic origin. As far as synthetic organic inhibitors concern, they are further divided as peptide type and not peptide type. Certain MDM2 inhibitors mimic the p53 topology and some do not.2

Till date, no proper chemical classification of MDM2 inhibitors is available. Hence, in this review we have tried to classify them based on their origin, chemical and functional types.

Types of Mdm2 Inhibitors

Basically, MDM2 inhibitors are classify according to natural origin or synthetic origin. They are further classify based upon their chemical characteristics and functionality.

Natural inhibitors

These are the natural products or natural compounds, isolated from the nature. MDM2 inhibitors belongs to the natural origin are come under this class.

Chalcone analogues

Chalcone based MDM2 inhibitors were the first reported natural MDM2 inhibitors (figure 1). These kinds of inhibitors have been studied extensively. In the various studies, chalcone based natural MDM2 inhibitors released the p53 from p53-MDM2 complex and re-established the p53 function. Various researchers also studied the boronic chalcone analogues.3

Figure 1

Structure of Chalcone


Isoliquiritigenin (4,2,4-trihydroxychalcone) is a natural chalcone (figure 2), isolated form the shallot and licorice root. It induces the p53 dependent cell cycle arrest and cell death in the liver cancer cells.4

Figure 2

Structure of iso-liquiritigenin



Chlorofusin was the second natural product, identified as MDM2 inhibitors. Chlorofusin was first isolated in 2001 by Duncan from the Fusarium sp. Microdocium caespitosum, a type of marine sponge.5

Later on, Williams and co-worker were also reported the chlorofusin. They had identified the chlorofusin after the testing of 53,000 extracts from the fermentation of a diverse collection of micro-organisms for MDM2 inhibitors activity.5 This novel metabolite was isolated from the microdochium caespitosum.

Chlorofusin contains the unnatural cyclic peptide and chromophore moieties (figure 3). In which, azaphilone derived chromophore linked through the terminal amine of ornithine to a cyclic peptide composed of nine amino acid residues.6 Two of the cyclic peptide amino acids possess a nonstandard or modified side chain, and four possess the D-configuration.7

Figure 3

Structure of Chlorofusin8


The full peptide and azaphilone structure are required for inhibition of the p53-MDM2 interaction. In the study, chlorofusin binds with the N-terminal region of the MDM2 protein and inhibits its activity.

Hexylitaconic acid

Hexylitaconic acid-(-) is a good MDM2 inhibitor from natural origin (figure 4). It was reported recently. Arthrinium sp. fungus was isolated from the marine sponge, and hexylitaconic acid was derived from the fermentation culture of this fungus.9

The result of various studies indicated that the hexylitaconic acid can effectively inhibit the p53-MDM2 interaction and can able initiate the p53 function.

Figure 4

Structure of hexylitaconic acid


Various derivatives of the hexylitaconic acid, like monomethyl ester, dihydro derivative and dihydro derivative of the monomethyl ester can’t inhibit the MDM2 function at µg concentrations.10 Two commercially available di-carboxylic acids derivatives (itaconic acid, succinic acid) of hexylitaconic acid are also not effective as MDM2 inhibitors at µg concentration.

Synthetic inhibitors

Synthetic MDM2 inhibitors are comes under this class. These types of inhibitors are designed and developed by the various researchers. They are further classified as peptide inhibitors and non-peptide (small organic) inhibitors.

Peptide inhibitors

These types of inhibitors are synthetic peptides (proteins). Peptides based inhibitors can be designed to successfully mimic the alpha helix topography of the p53 protein. So, they can be developed as potent p53-MDM2/X interaction inhibitors.11

MDM2 binding site on p53 protein was mapped by the Novartis group. They mapped it by using the synthetic peptide libraries derived from the N-terminal region of p53.12 The most active peptide obtained from this study (figure 5), was having the 28 folds greater MDM2 inhibitory property than the wild type p53-derived peptide.

Figure 5

Structure of peptide inhibitor reported by Novartis


Peptides based MDM2 inhibitors have a structural similarity with the p53 sequence, so it easily permits the entry into the cells. They can mimic the conformation of the p53 helix and cause non-genotoxic activation p53 function. These types of inhibitors have an advantage of the possibility of high specificity, potency and low toxicity.13 These synthetic linear peptides can adopt a helical conformation and inhibit the p53-MDM2 interaction.

Use of this linear peptide as drugs has faced some problems, which are:

  1. Peptide can adopt random conformations in solution.

  2. Peptide suffers from low cell permeability

  3. Peptides are proteolytically unstable.

Strategy to overcome these problems, is to staple the hydrocarbon with the peptide. Hydrocarbon linker holds the peptide in a helical conformation so it will be always in the helical conformation. And it can be able to permanently bind with MDM2. Hydrocarbon stapling will inhibit the proteolytic degradation and increase the cellular uptake.14

Other strategy to overcome the rapid enzymatic degradation is to use D-amino acids for synthetic peptides chain. This type of peptides are far more stable to proteolytic degradation, as enzymes present in the body are only capable of processing L-amino acids due to their stereo-specificity.

These are some of the approaches to stabilize the peptides.15 Though many of peptides are reported, which can inhibit p53-MDM2 interaction. But there are currently no peptide based inhibitors in clinical trials.

Organic inhibitors (Non-peptide Inhibitors)

These are the synthetic organic (non-peptidic) MDM2 inhibitors. These types of inhibitors are subdivided according to their alpha helix mimetic property. So, they further classified as Non α-helix mimetics and α-helix mimetics.

Non α-helix mimetics (Functional mimetics)

These MDM2 inhibitors are small organic (non-peptide) compounds that place substituents in the same spatial orientation as the p53 helix. They do not mimic the α-helix topography. These types of compounds are the competitive inhibitors of MDM2 protein.

By using the High Throughput Screening (HTS) campaigns at Hoffmann-La Roche, Vassilev and colleagues were discovered the first compound of this class called as Nutlin. Nutlin contains the cis-imidazoline (4,5-dihydroimidazoline) moiety. Nutlins mimic the three main amino acid residues on p53 (i, i+4, i+7), involved in its interaction with MDM2.16 Hence, it shows 3 pocket binding. And inhibit the p53-MDM2 interaction. Nutlin group contains three compounds, Nutlin-1, Nutlin-2 and Nutline-3 (figure 6). Among them, Nutlin-3 is most potent compound (IC50 — 90nM).

Figure 6

Structures of nutlins


Assay of nutlin on various cell lines, shows the dose dependent MDM2 inhibition and activation of wild type p53 protein function. Currently, there are total seven compounds of this class, which are under clinical trials.

In our study, we have designed and developed this type of MDM2 inhibitors. Therefore in this thesis, MDM2 inhibitors of this class will be discussed in details.

A-helix mimetics

Inhibitors pertaining this class are organic in nature and mimics the α-helix of p53. They mimic the topography of α-helix and can position the substituents in the same spatial orientation as the 3 different interaction points of p53 helix. With contrast to Functional mimetics, these types of inhibitors are generally more extended.17

Hamilton and co-workers discovered the first compound of this class (α-helix mimetics). And it was the terphenyl derivatives. Other reported compounds of this class contain the various chemical derivatives like pyrrolopyrimidine derivatives, spirooligomer derivatives and oligobenzamide derivatives. Oligobenzamide scaffold was reported by wilson and co-workers.18

Figure 7

Structures of α-helix mimetics inhibitors15


This class of compounds has a good potential of inhibiting the p53-MDM2 interaction effectively.


We can classify the MDM2 inhibitors as per their origin and their chemicals class. Then they can be further sub-divided as per peptide nature or small organic molecule. Synthetic non-peptide inhibitors consist of the diversified chemical groups and moieties. So, it provided the separate sub-type of the inhibitors. As a whole MDM2 inhibitors can be also divide as α-helix (p53) mimetics and non-mimetics. There are totally 09 MDM2 inhibitors under clinical trials, among them 08 are non-peptide small organic compound and 01 is synthetic (stapled) peptide type.

Source of Funding


Conflict of Interest



First Author (Chirag J. Gohil) thankful to Dr. C. N. Patel & Dr. D. J. Sen for guidance provided by them as part of my Doctoral Progress Committee.

First Author also feels very thankful to Dr. M. N. Noolvi (supervisor & guide) for his support and assistance.



C Sen Improved Weighted Sum Multi ObjectiveProgrammingInt J Modern Trends Sci Technol202171111310.46501/ijmtst070126


C J Gohil M N Noolvi Synthesis of New Diaryl Derivatives Comprising Imidazothiadiazole Moiety as Potential Anticancer AgentsInt J Pharm Chem Anal2015228496


C J Gohil M N Noolvi Aromatase Inhibitors: A Safer Approach for the Treatment of Breast CancerInt J Pharm Chem Anal20152492198


K Nandi D J Sen D Saha Liquid Tissue Running 24×7 In-vivo Is the Heart Touching Heart ThrobWorld J Pharm Med Res2021711071910.17605/OSF.IO/6DPWS


C J Gohil M Noolvi Selective Cancer Treatment by Boron Neutron Capture Therapy - a ReviewInt J Pharm Chem Anal2015231368


C J Gohil Review on LeishmaniasisBiomed J Sci Tech Res2017151453510.26717/bjstr.2017.01.000460


C J Gohil M N Noolvi Types of p53/MDM2 Interaction InhibitorsEur J Biol Med Pharm Sci20185111437


A Beloglazkina N Zyk A Majouga E Beloglazkina Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein InteractionMolecules2020255121110.3390/molecules25051211


D Bliman M Pettersson M Bood M Grøtli 8-Bromination of 2,6,9-trisubstituted purines with pyridinium tribromideTetrahedron Lett2014201413


C J Gohil M N Noolvi Master Regulator of Apoptosis and its Application in Cancer TherapyInt J Pharm Biol Arch201910315464


E Danelius M Pettersson M Bred J Min M B Waddell R K Guy Flexibility is important for inhibition of the MDM2/p53 protein–protein interaction by cyclic β-hairpinsOrg Biomol Chem20161444103869310.1039/c6ob01510g


C J Gohil M N Noolvi Non peptidic small molecular inhibitors of the p53-MDM2 interactionInt J Pharm Chem Anal202064104910.18231/j.ijpca.2019.019


C J Gohil M N Noolvi Novel Corona Virus and Its Druggable TargetsCurr Opin Virus Infect Dis202020203513


M Pettersson D Bliman J Jacobsson J R Nilsson J Min L Iconaru 8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 Interaction.PLoS ONE2015101244234


C J Gohil M N Noolvi Design and In Silico Study of the Novel Small Molecular MDM2 InhibitorsBiointerface Res Appl Chem11180526410.33263/BRIAC111.73567356


J J Gohil C J Gohil Cytokine Storm: A Suicidal Immune Response to Novel Corona VirusGlob J Med Res202121131710.34257/gjmrbvol21is1pg31


C J Gohil M N Noolvi SOLVENT-FREE SYNTHESIS OF AMIDE: A NOVEL TECHNIQUE OF GREEN CHEMISTRYAsian J Pharm Clin Res20211459910210.22159/ajpcr.2021.v14i5.40688


M Pettersson M Quant J Min L Iconaru W Richard M B Waddell Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 InteractionPLoS ONE20151010013786710.1371/journal.pone.0137867


© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Wiki in hindi